Get started
Oragenics Inc.OO

Oragenics Inc.

1.16USDR
−0.14−10.77%
At close at Aug 8, 23:59 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

OGEN trade ideas

OGEN Study by Making ProfitThis is my Daily Portfolio Trade Study. OGEN still have that gap at .69 and an old support at .45 cents. Today the SMA line worked as a support at .52 and now for tomorrow can work as a support at .53. We faced today a strong resistance at .59 , the RSI is at 47 and the MACD looked bearish at the close today. *Personal Opinion* The company received great and positive news this morning about their product in phase 2 (AGO13). They will present interim data on AGO13 at the European Society of Medical Oncology Congress on Sept 27th to Oct 1st of 2019. All these data is positive so I'm expecting an increase of the SP during EOW or by the end of the next week. The Chart looks good in my opinion and the stock didn't increased that much today because of the lo volume 900k aprox. The stock have good news and a decent chart, all it need is volume. -Important- ! Don't buy because of my study, do your own DD !
ALong
by Making_Profit
OGEN want easy 150% gain in 3 months? or 80% in 10 days? READDo your own DD on this stock and the catalyst but chart, data, news, pipeline, timeline..... all together say BUY @ 0.52 now on STUPID low volume, Cash out @ 0.75-0.80 Next week. Rebuy on dip to 0.69 and hold til Phase 2 data released early Nov with earnings report and cash out @ 3.09 then rebuy in Dec for 1.50 and hold til summer for 3.50 and sell again... LONG TERM (3-5 years) this is a 15-20 PT company with major buyout options soon available in 2020.
ALong
by TheStockMarketSniper
1
$OGEN ON THE WATCHLIST FOR BREAKOUT IN ORAGENICS INC******HOT STOCK ON THE WATCHLIST FOR A SWING TRADE IN THE WEEKS TO COME, SPECULATION AND RUMORS HAVE BROUGHT IT THE ATTENTION OF MANY AND SOME ACCUMULATION HAS STARTED TO TAKE PLACE. JUST LIKE MOST BIO STOCKS, AMEX:OGEN TENDS TO MOVE VERY FAST FOR GREAT GAINS ON TRIAL AND DATA RELEASE, SO SET YOUR ALERTS FOR SPIKES. AVERAGE ANALYSTS PRICE TARGET $2.50 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY PROFILE Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
A
by DEXWireNews
1
$OGEN On the watch-list for a substantial move higher . H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc (OGEN) today and set a price target of $2. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.38. Selvaraju observed: “We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the incidence of 2 data may serve as one of the two pivotal data sets required to support regulatory filing, in our view. AG013 has been granted Fast Track designation in the U.S. and Orphan Drug status in Europe. In the wake of this update, we reiterate our Buy rating and $2 price target. Preclinical data of lantibiotics published. Lantibiotics have been developed to possess both strong antimicrobial properties as well as the ability to evade common resistance mechanisms. Last week, preclinical data of the company’s lantibiotic compound, OG253, were published in Toxicology and Applied Pharmacology.” ANALYSTS RATING BUY ANALYSTS PRICE TARGET $2.50 COMPANY PROFILE AMEX:OGEN IS focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
ALong
by DEXWireNews